Education
About Us
Working with TipRanks
Follow Us
Caribou Biosciences (CRBU)
NASDAQ:CRBU
Total Valuation
Caribou Biosciences has a market cap or net worth of $119.05M. The enterprise value is $398.86M.
Market Cap$119.05M
Enterprise Value$398.86M
Share Statistics
Caribou Biosciences has 93,004,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding93,004,600
Owned by Insiders8.16%
Owned by Institutions17.31%
Financial Efficiency
Caribou Biosciences’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -58.65%.
Return on Equity (ROE)-0.59
Return on Assets (ROA)-0.48
Return on Invested Capital (ROIC)-58.65%
Return on Capital Employed (ROCE)-0.59
Revenue Per Employee67.99K
Profits Per Employee-1.01M
Employee Count147
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Caribou Biosciences is -0.96. Caribou Biosciences’s PEG ratio is 0.26.
PE Ratio-0.96
PS Ratio0.00
PB Ratio1.15
Price to Fair Value0.57
Price to FCF-4.03
Price to Operating Cash Flow-4.53
PEG Ratio0.26
Income Statement
In the last 12 months, Caribou Biosciences had revenue of 9.99M and earned -149.10M in profits. Earnings per share was -1.65.
Revenue9.99M
Gross Profit6.07M
Operating Income-166.62M
Pretax Income-149.11M
Net Income-149.10M
EBITDA-166.62M
Earnings Per Share (EPS)-1.65
Cash Flow
In the last 12 months, operating cash flow was -137.72M and capital expenditures -4.47M, giving a free cash flow of -142.20M billion.
Operating Cash Flow-137.72M
Free Cash Flow-142.20M
Free Cash Flow per Share-1.53
Dividends & Yields
Caribou Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.33
52-Week Price Change-28.34%
50-Day Moving Average0.96
200-Day Moving Average1.49
Relative Strength Index (RSI)65.53
Average Volume (3m)1.09M
Important Dates
Caribou Biosciences upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Caribou Biosciences as a current ratio of 7.16, with Debt / Equity ratio of 7.36%
Current Ratio7.16
Quick Ratio7.16
Debt to Market Cap<0.01
Net Debt to EBITDA-0.06
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Caribou Biosciences has paid -9.00K in taxes.
Income Tax-9.00K
Effective Tax Rate<0.01
Enterprise Valuation
Caribou Biosciences EV to EBITDA ratio is -0.92, with an EV/FCF ratio of -1.07.
EV to Sales15.39
EV to EBITDA-0.92
EV to Free Cash Flow-1.07
EV to Operating Cash Flow-1.11
Balance Sheet
Caribou Biosciences has $208.47M in cash and marketable securities with $26.22M in debt, giving a net cash position of -$182.24M billion.
Cash & Marketable Securities$208.47M
Total Debt$26.22M
Net Cash-$182.24M
Net Cash Per Share-$1.96
Tangible Book Value Per Share$2.80
Margins
Gross margin is -225.07%, with operating margin of -1667.16%, and net profit margin of -1491.95%.
Gross Margin-225.07%
Operating Margin-1667.16%
Pretax Margin-1492.04%
Net Profit Margin-1491.95%
EBITDA Margin-1667.16%
EBIT Margin-1667.16%
Analyst Forecast
The average price target for Caribou Biosciences is $5.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$5.20
Price Target Upside288.06% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-70.31%
EPS Growth Forecast-11.68%